Navigation Links
Sharp Edge Labs and SpectraGenetics Sign Agreement to Provide Better Assays for Studying G-Protein Coupled Receptors
Date:10/29/2013

PITTSBURGH, Oct. 29, 2013 /PRNewswire-iReach/ -- Sharp Edge Labs and SpectraGenetics, two Pittsburgh-based biotechnology companies, have entered into an Assay Development Agreement that will allow the companies to offer their industry leading assays for studying the detailed function of an important class of pharmaceutical targets, the G-Protein Coupled Receptors, or GPCRs.  GPCRs are the most common target of today's blockbuster drugs, including drugs for diseases ranging from hypertension and allergy to migraines, pain and cancer.  "While GPCRs are among the most-studied drug targets, we are just now learning important new aspects of how they work.  These assays provide unprecedented detail in understanding these new aspects of activity for the industry's most valuable drug targets" said Dr. Scott Sneddon, Ph.D., J.D., President and CEO of Sharp Edge Labs.  

(Photo: http://photos.prnewswire.com/prnh/20131029/MN04907)

"Working together, we can now offer a comprehensive set of tools for pharmaceutical and academic researchers including reagents and read-to-run assay kits, as well as assay services for profiling and screening compounds" added Dr. Reid Asbury, Ph.D., CEO of SpectraGenetics.  "Several large-pharma customers are already using the technology to study so-called 'ligand bias' or 'functional selectivity' of GPCRs.  By combining SpectraGenetics' catalog of over 150 GPCRs with Sharp Edge Labs' assay development expertise, we believe we can help researchers address any question in this important new field of drug research" he added.

SpectraGenetics provides research reagents to the pharma/biotech industry and academic labs.  SpectraGenetics has a large catalog of tagged genes, including a large selection of tagged GPCRs.   Sharp Edge Labs is the exclusive licensee of the Fluorogen Activating Peptide technology from CMU and provides assay products and services for pharma/biotech researchers in the areas of Receptors, Ion Channels and Transporters.  The company's web-sites are www.spectragenetics.com and www.sharpedgelabs.com.  Detailed images of the technology in use  suitable for print or web publication can be found at www.sharpedgelabs.com/media-images

Media Contact: Scott Sneddon, PhD, JD, Sharp Edge Labs, Inc., 412-475-9733, scott@sharpedgelabs.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Sharp Edge Labs, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Rehrig Pacific Company Receives FDA Approval for New Reusable Sharps Container
2. Sharp Rees-Stealy Medical Centers Launches Asthmapolis Mobile Asthma Management Program
3. Safe in Commons "The Unfinished Agenda: Addressing the Challenges" Crystalizes Call for Unified Protection Against Needlestick and Sharps Injuries
4. Brain Resource Featured as Market Leader in SharpBrains New Report on The State of the Digital Brain Health Market 2012-2020
5. Daniels Sharpsmart Canada Awarded HealthPro Contract And Appoints Daniel Kennedy CEO Of Daniels Canada
6. Circassia Appoints Stewart Sharpe as Vice President Commercial Operations
7. Study Confirms Daniels Sharpsmart Helps Hospitals Reduce Carbon Footprint
8. Philips and Infraredx sign agreement for the resale of Infraredxs TVC Imaging System integrated with Philips interventional X-ray systems
9. Valeant Pharmaceuticals Announces Settlement Agreement With Anacor
10. InCube Labs Enters into an Agreement with the Engineering Research Center for Revolutionizing Metallic Biomaterials
11. Bioject Enters Into Agreement With Fondaco PTE LTD For Distribution Of Full Line Of Needle Free Injection Devices In Asia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... 2017  New York City-based market research firm Kalorama Information ... aware of.  From new products to new costs, to the ... recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment Arriving ... the impact the growing population and, to a more extreme ...
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how to ... shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To ... Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and educational ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... torn anterior cruciate ligament (ACL) offer patients improved quality of life five years ... for Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... in which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... to remote participants for real-time collaboration and immediate decision-making requirements. While never ...
Breaking Medicine News(10 mins):